163 related articles for article (PubMed ID: 35123640)
1. [Kinetics of MDSC in Patients Treated Steroids-Ruxolitinib as the First Line Therapy for aGVHD].
Yang JJ; Peng B; Fang S; Wei Y; Wang H; Zhao YX; Qian K; Wen YN; Liu DH; Dou LP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):276-285. PubMed ID: 35123640
[TBL] [Abstract][Full Text] [Related]
2. Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial.
Dou L; Peng B; Li X; Wang L; Jia M; Xu L; Li F; Liu D
Trials; 2022 Jun; 23(1):470. PubMed ID: 35668528
[TBL] [Abstract][Full Text] [Related]
3. Elevated REG3α predicts refractory aGVHD in patients who received steroids-ruxolitinib as first-line therapy.
Yang J; Peng B; Wang L; Li X; Li F; Jin X; Jia M; Xu L; Dou L; Liu D
Ann Hematol; 2022 Mar; 101(3):621-630. PubMed ID: 34816294
[TBL] [Abstract][Full Text] [Related]
4. Ruxolitinib in the management of steroid-resistant/-dependent acute and chronic graft-versus-host disease: results of routine practice in an academic centre.
Leung GMK; Sim JPY; Hwang YY; Chan TSY; Lie AKW; Tse E; Kwong YL
Ann Hematol; 2022 Jan; 101(1):155-163. PubMed ID: 34767056
[TBL] [Abstract][Full Text] [Related]
5. The Effectiveness of Ruxolitinib for Acute/Chronic Graft-versus-Host Disease in Children: A Retrospective Study.
Yang W; Zhu G; Qin M; Li Z; Wang B; Yang J; Wang T
Drug Des Devel Ther; 2021; 15():743-752. PubMed ID: 33654380
[TBL] [Abstract][Full Text] [Related]
6. Ruxolitinib: a potential treatment for corticosteroid refractory acute graft-versus-host disease.
Abedin SM; Hamadani M
Expert Opin Investig Drugs; 2020 May; 29(5):423-427. PubMed ID: 32293938
[TBL] [Abstract][Full Text] [Related]
7. Ruxolitinib treatment for SR-aGVHD in patients with EBV-HLH undergoing allo-HSCT.
Meng G; Wang J; Wang X; Wang Y; Wang Z
Ann Hematol; 2020 Feb; 99(2):343-349. PubMed ID: 31879790
[TBL] [Abstract][Full Text] [Related]
8. Real-world experience with ruxolitinib therapy for steroid-refractory acute graft versus host disease.
Murray A; Linn SM; Yu B; Novitzky-Basso I; Mattsson J; Kennah M; Elemary M; White J; Lemieux C; Jamani K; Kim DDH
Bone Marrow Transplant; 2024 Jun; 59(6):759-764. PubMed ID: 38402344
[TBL] [Abstract][Full Text] [Related]
9. Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia.
Zhang B; Chen L; Zhou J; Zu Y; Gui R; Li Z; Wang J; Yu F; Zhang Y; Zhao H; Ji Z; Song Y
Sci Rep; 2021 Apr; 11(1):8501. PubMed ID: 33875780
[TBL] [Abstract][Full Text] [Related]
10. Ruxolitinib in children with steroid-refractory acute graft-versus-host disease: A retrospective multicenter study of the pediatric group of SFGM-TC.
Laisne L; Neven B; Dalle JH; Galambrun C; Esvan M; Renard C; Rialland F; Sirvent A; Gandemer V;
Pediatr Blood Cancer; 2020 Sep; 67(9):e28233. PubMed ID: 32614145
[TBL] [Abstract][Full Text] [Related]
11. JAK1/2 inhibitor ruxolitinib promotes the expansion and suppressive action of polymorphonuclear myeloid-derived suppressor cells via the JAK/STAT and ROS-MAPK/NF-κB signalling pathways in acute graft-versus-host disease.
Cao Y; Wang J; Jiang S; Lyu M; Zhao F; Liu J; Wang M; Pei X; Zhai W; Feng X; Feng S; Han M; Xu Y; Jiang E
Clin Transl Immunology; 2023; 12(2):e1441. PubMed ID: 36855558
[TBL] [Abstract][Full Text] [Related]
12. [The Characteristics of T Lymphocyte Reconstitution after Haploid Hematopoietic Stem Cell Transplantation in SAA and Its Relationship with aGVHD].
Tian Q; Zhu QJ; Wang T; Gong R; Tian WW; Gao ZL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):532-538. PubMed ID: 37096530
[TBL] [Abstract][Full Text] [Related]
13. Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial.
Teshima T; Onishi Y; Kato K; Taniguchi S; Miyamura K; Fukushima K; Kato J; Ishikawa T; Doki N; Nakamae H; Maeda Y; Inamoto Y; Okada M; Maki A; Shimada F; Tajima T; Wroclawska M; Zeiser R; Onizuka M
Int J Hematol; 2024 Jul; 120(1):106-116. PubMed ID: 38796666
[TBL] [Abstract][Full Text] [Related]
14. Second-line therapy for patients with steroid-refractory aGVHD: systematic review and meta-analysis of randomized controlled trials.
Luo C; Huang X; Wei L; Wu G; Huang Y; Ding Y; Huang Z; Chen J; Li X; Zou Y; Xu S
Front Immunol; 2023; 14():1211171. PubMed ID: 37409129
[TBL] [Abstract][Full Text] [Related]
15. Ruxolitinib Treatment of Steroid-Refractory Graft-versus-Host Disease in Children: A Case Series and Review of the Literature.
Yan WL; Zhao FY; Gu ME; Liu N; Guo XP; Xu XJ
Paediatr Drugs; 2023 Sep; 25(5):577-584. PubMed ID: 37284944
[TBL] [Abstract][Full Text] [Related]
16. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).
von Bubnoff N; Ihorst G; Grishina O; Röthling N; Bertz H; Duyster J; Finke J; Zeiser R
BMC Cancer; 2018 Nov; 18(1):1132. PubMed ID: 30453910
[TBL] [Abstract][Full Text] [Related]
17. ECP versus ruxolitinib in steroid-refractory acute GVHD - a retrospective study by the EBMT transplant complications working party.
Penack O; Peczynski C; Boreland W; Lemaitre J; Afanasyeva K; Kornblit B; Jurado M; Martinez C; Natale A; Pérez-Simón JA; Brunello L; Avenoso D; Klein S; Ozkurt ZN; Herrera C; Wichert S; Chiusolo P; Gavriilaki E; Basak GW; Schoemans H; Koenecke C; Moiseev I; Peric Z
Front Immunol; 2023; 14():1283034. PubMed ID: 38149251
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of ruxolitinib for steroid-refractory graft-versus-host disease: Systematic review and meta-analysis of randomised and non-randomised studies.
Zhang MY; Zhao P; Zhang Y; Wang JS
PLoS One; 2022; 17(7):e0271979. PubMed ID: 35905125
[TBL] [Abstract][Full Text] [Related]
19. Increased Galectin-9 expression, a prognostic biomarker of aGVHD, regulates the immune response through the Galectin-9 induced MDSC pathway after allogeneic hematopoietic stem cell transplantation.
Yin J; Li L; Wang C; Zhang Y
Int Immunopharmacol; 2020 Nov; 88():106929. PubMed ID: 32889240
[TBL] [Abstract][Full Text] [Related]
20. Ruxolitinib Pharmacokinetics and Pharmacodynamics in Children with Acute and Chronic Graft-versus-Host Disease.
Cook E; Dong M; Chiang SCC; Luedeke D; Lake KE; Hoerth C; Deavy M; Setchell KDR; Zhao J; Punt N; Galletta T; Teusink-Cross A; Davies SM; Marsh RA; Mehta P; Khandelwal P
Transplant Cell Ther; 2024 May; 30(5):528.e1-528.e12. PubMed ID: 38401793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
